Recent

% | $
Quotes you view appear here for quick access.

Opexa Therapeutics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dont_be_a_poser_dude dont_be_a_poser_dude Sep 8, 2009 3:53 PM Flag

    Tovaxin has nothing to do with Novartis

    Read 'em and weep.....

    More recently, Novartis and Opexa Therapeutics (OPXA) inked a deal giving Novartis control of Opexa’s stem cell program, including its Tovaxin MS therapy. Tovaxin is a personalized T-cell vaccine for relapsing remitting MS prepared by expanding specific subsets of myelin-reactive T-cells. Attenuated cells are reintroduced with a goal of setting up an anti-idiotype network to shift a TH1 mediated response to a Th2 response.

    In 2008, the TERMS phase II study suggested the strong possibility of a therapeutic response similar to that seen with current platform therapies and with no significant side effects. Initiation of a phase III study in relapsing remitting MS is likely by early next year and will serve as a much bigger catalyst for Opexa than for Novartis.

 
OPXA
3.07-0.22(-6.69%)May 26 4:00 PMEDT